Annals of Clinical Microbiology and Antimicrobials

Table 3 Antimicrobial drug susceptibility profiles (MICs in mg/L) for clinical isolates and transconjugants

From: Transmission and characterization of bla _NDM-1 in Enterobacter cloacae at a teaching hospital in Yunnan, China

Isolate no.	VITEK2										E test
Isolate no.	PIP	TCY	ATM	CAZ	CIP	AMK	MEM	IMP	ETP	TGC	MEM	IMP	ETP
T1	≥128	≥16	≥64	≥64	≥4	16	8	8	≥8	1	>32	32	>32
T2	≥128	4	≥64	≥64	≥4	≤2	≥16	≥16	≥8	1	>32	>32	>32
T3	≥128	≥16	≥64	≥64	≥4	≥64	8	≥16	≥8	≥8	>32	>32	>32
T4	≥128	8	≥64	≥64	≥4	4	≥16	≥16	≥8	1	>32	24	>32
T5	≥128	≥16	16	≥64	≥4	4	≥16	≥16	≥8	2	>32	>32	>32
T6	≥128	≥16	≥64	≥64	≥4	16	≥16	≥16	≥8	1	32	>32	>32
T7	≥128	≥16	16	≥64	≥4	16	≥16	≥16	≥8	2	>32	>32	>32
T8	≥128	≥16	≥64	≥64	≥4	16	≥16	≥16	≥8	1	>32	>32	>32
T9	≥128	≥16	≤1	≥64	0.5	≤2	≥16	≥16	≥8	1	>32	>32	>32
T10	≥128	4	≥64	≥64	≥4	≤2	4	4	≥8	2	6	8	8
T1-EC600	≥128	≤1	≤1	≥64	0.5	≤2	8	≥16	≥8	1	8	8	8
T2-EC600	≥128	≤1	32	≥64	0.5	≤2	≥16	≥16	≥8	1	8	16	>32
T3-EC600	≥128	≤1	≤1	≥64	0.5	≤2	8	≥16	≥8	2	16	16	>32
T4-EC600	≥128	≥16	32	≥64	0.5	≤2	8	≥16	≥8	1	>32	6	8
T5-EC600	≥128	≤1	≤1	≥64	0.5	≤2	8	≥16	≥8	2	>32	>32	>32
T6-EC600	≥128	≤1	≤1	≥64	0.5	≤2	≥16	≥16	≥8	1	>32	>32	>32
T7-EC600	≥128	≤1	≤1	≥64	0.5	≤2	≥16	≥16	≥8	1	24	8	8
T8-EC600	≥128	≤1	≤1	≥64	0.5	≤2	8	≥16	≥8	1	>32	>32	>32
T9-EC600	≥128	≤1	≤1	≥64	0.5	≤2	≥16	≥16	≥8	1	24	>32	24
T10-EC600	≥128	≤1	≤1	≥64	0.5	≤2	≥16	≥16	≥8	1	>32	>32	16
EC600	≤4	≤1	≤1	≤1	≤0.25	≤2	≤0.25	≤1	≤0.5	≤0.5	0.032	0.019	0.008
ATCC25922	≤4	≤1	≤1	≤1	≤0.25	≤2	≤0.25	≤1	≤0.5	≤0.5	0.032	0.019	0.008

EC600 Escherichia coli 600, T1-EC600 the transconjugants of T1 strain, PIP piperacillin, TCY tetracycline, ATM aztreonam, CAZ ceftazidime, CIP ciprofloxacin, AMK amikacin, MEM meropenem, IPM imipenem, ETP ertapenem, TGC tigecycline

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com